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Abstract
Early and accurate detection of bacterial infections can help save lives, prevent
the spread of disease, and decrease the overuse of antibiotics. Our team at the Los
Alamos National Laboratory has developed novel assays to detect bacterial biomarkers
from patient blood at the point-of-care in order to facilitate a universal diagnostic
platform. However, these biomarkers are amphiphilic in nature, and this biochemical
property causes them to be sequestered by high-density and low-density lipoproteins
(HDL and LDL) in the host’s blood. Extraction of the bacterial biomarkers from the
lipoprotein complexes is thereby required for the development and deployment of a
diagnostic platform.
Accordingly, our team has developed a sample processing protocol to extract the
biomarkers of interest; however, this procedure requires multiple pipetting, mixing, and
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centrifugation steps that must be performed by hand in a well-equipped laboratory. It also
utilizes several chemical reagents, including chloroform and methanol, as well as
potentially-infectious human blood. For use in resource-poor settings with minimallytrained personnel, sample processing should be automated in order to guarantee proper
treatment of the sample and safety of the staff involved.
Presented in this work is the development of a semi-automated microfluidic
sample processing platform for the extraction of amphiphilic bacterial biomarkers. A
fully automated system would require two phase separation steps and a re-suspension
step to be integrated into a microfluidic platform. Herein, a novel cross-flow filtration
scheme was designed to achieve phase separations on a microfluidic device. The devices
were fabricated using a combination of laser-based microfabrication and lamination
methods. We have taken a stepwise approach to determine the optimal combination of
membrane material, membrane pore size, fabrication methods, and geometric design
parameters that result in consistent performance. To demonstrate proof of principle, two
major phase separations were performed: blood/serum separation, and biomarker
extraction. Device materials and surface chemistry were determined to be suitable for this
application, as measured by biomarker retention experiments.
This study provides the groundwork for a potentially fully-automated sample
processing platform for amphiphilic biomarker extraction from whole blood. The crossflow filtration platform is a promising design for the complete automation of sample
processing because it requires only 90µL of whole blood, is modular, and does not
interfere with amphiphile detection. It is simple to manufacture, disposable, pump-free,
and does not require the dilution of blood.
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Chapter 1: Introduction

1.1: Biomarker Detection
1.1.1: Motivation
Early and accurate detection of bacterial infections is necessary to guide treatment
decisions and prevent the evolution of antibiotic-resistant organisms.1–6 Novel assays
developed by our team at the Los Alamos National Laboratory are able to quickly detect
biomarkers indicative of infection from patient blood, and can be adapted for use at the
point-of-care. These biomarkers are lipid-based, and their amphiphilic biochemistry
causes them to be sequestered by host lipoprotein carriers, including high-density and
low-density lipoproteins (HDL and LDL).7,8 In order to detect amphiphilic biomarkers in
human blood, the sample must be processed to first separate serum from blood, and then
extract biomarkers from serum.7 Our team has developed a protocol for this separation
and extraction, but the method requires highly trained personnel and a multi-step
benchtop procedure. The automation of sample preparation will allow for this method to
be effective for use at the point-of-care (especially in resource-poor settings), save time,
and ensure user safety (which is of importance when handling potentially infectious
human blood). It will also facilitate quicker diagnoses, leading to improved outcomes for
patients. Early detection and proper treatment of bacterial infections is essential to help
prevent the spread of infection, save lives, and lessen the burden of outbreaks.
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1.1.2: Amphiphilic Biomarkers of Interest
Bacteria have traditionally been categorized into Gram-negative, Gram-positive,
or Gram-indeterminate based on the structure of their cell walls/membranes, which
causes them to stain differently under Gram staining techniques. 9 Each class of bacteria
secretes different cell wall components in the host during the course of infection, and
these biomarkers are recognized by innate immune receptors, resulting in cytokine
signaling.1 Thus, the variability in cell wall composition is responsible for differential
immune responses in infected individuals.
Gram-negative bacteria are characterized by two cell membranes: a thin inner
membrane containing peptidoglycan, and an outer membrane composed of about 70%
lipopolysaccharide (LPS), a biomarker of interest, in addition to proteins and
phospholipids.9 Gram-positive bacteria lack this outer membrane, but contain a
biomarker of interest called lipoteichoic acid (LTA) that extends from the cell membrane
through the peptidoglycan wall.9 Lipoarabinomannan (LAM) is a similar molecule found
in Mycobacterium tuberculosis, a Gram-indeterminate bacteria that is the causative agent
of tuberculosis.10 LPS, LTA, and LAM are virulence factors that fall into the category of
molecules called pathogen-associated molecular patterns (PAMPs). PAMPs are bacterial
cell products that are recognized by the host’s innate immune system during infection. 11
After the rapid response of the innate immune system, the adaptive immune system
responds to eliminate the infectious agent. 12 Thus, LPS, LTA, and LAM are ideal targets
for diagnostics because they are released early in infection, are indicative of active
infection, and are more stable than protein biomarkers.1
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The structure of some of these amphiphiles, such as LPS, have been well
characterized. LPS will serve as an example structure for all three major amphiphilic
biomarkers. Three distinct segments of LPS have been identified (Figure 1). The lipid A
portion is a highly conserved endotoxin made of acyl chains of varying lengths and
patterns. The core oligosaccharide region is covalently attached to lipid A and is subdivided into an inner core, which is proximal to lipid A, and an outer core, which is distal
to lipid A. The inner core is conserved and consists of a high percentage of rare sugars,
especially 3-deoxy-D-manno-octulosonic acid and L-glycero-D-manno heptose. The
outer core consists of common sugars such as hexoses. The third portion of LPS is the
furthest from the bacterial surface and is called the O-polysaccharide. The Opolysaccharide varies between bacterial serotypes and consists of one to eight repeating
glycosyl units. Indeed, the different O-polysaccharide structures are responsible for the
hundreds of different serotypes of Gram-negative bacterial species. The O-polysaccharide
is also referred to as the O-antigen, since it is the target of the host’s innate immune
system.13 This structure is important for understanding the biochemistry of the target
biomarkers and their interactions with components of host blood.

Figure 1: Schematic representation of lipopolysaccharide. Figure adapted from
Erridge et al. 2002.
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1.1.3: Inflammatory Response of Host
Upon exposure to a Gram-negative bacterial pathogen, LPS binding protein
(LBP) present in human serum sequesters LPS from the bacterial membrane and delivers
it to receptors for LPS.13 Also, high-density and low-density lipoproteins (HDL and LDL)
sequester circulating LPS in order to mediate macrophage activity. If left unconstrained,
the inflammatory response could cause septic shock and even death. In this way, the
host’s lipoproteins serve as a form of protection against the overproduction of
inflammatory molecules such as cytokines. 14
As mentioned earlier, LPS is a PAMP and is recognized by the host innate
immune response. This recognition is mediated by a family of transmembrane receptors
called Toll-like receptors (TLRs) that initiate the subsequent signaling cascade.12 The
majority of serotype-specific LPS molecules are recognized by TLR4; however, two
exceptions have been found to bind TLR2.13 The focus of this overview will be on TLR4
receptors.
LPS bound to LBP is brought to extracellular CD14 proteins, which are
associated with a TLR4 receptor on monocytic cells. CD14 cleaves large LPS micelles
into monomers for presentation to the TLR4-MD-2 complex.12 MD-2 is a protein that can
non-covalently associate with TLR4 or form a complex with LPS in the absence of
TLR4. Upon binding of LPS, TLR4 dimerizes, allowing intracellular Toll-interleukin-1
receptor (TIR) domains to begin mediating signal transductor adaptor proteins. 15 Binding
of LPS to this complex activates a variety of cellular responses, including nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB) and interferon regulatory factor
3 (IRF3), both of which affect DNA transcription for cytokine production.12 Figure 2
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illustrates the recognition of LPS by the TLR4-MD-2 complex. The rapid immune
response produced by PAMPs are part of what makes them attractive for diagnostic
applications.

Figure 2: Illustration of TLR4-MD-2 complex recognition of LPS. Figure adapted
from Lu et al. 2008.

1.2: Common Methods for Detecting Bacterial Infections
Presented in this section is an overview of commonly-used detection methods for
bacterial infections. This overview is not an exhaustive discussion, as that is beyond the
scope of this thesis.

1.2.1: Bacterial Cell Culture
Traditionally, bacterial infections of the blood have been detected by culturing
and processing large blood samples. The blood samples are quickly transferred to a
nutrient medium for bacterial cell culturing. Standard cultures require 48-72 hours to
provide enough growth for analysis; therefore, treatment often needs to begin before a
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final diagnosis is confirmed.16 Some cultures, such as Helicobacter pylori, the bacteria
that causes the majority of gastrointestinal ulcers, take five days to grow.17 Even more
concerning, Mycobacterium tuberculosis takes up to 6 weeks.18–20 There are still more
species of bacteria that are unculturable in a laboratory setting, knowledge of which is
only known from molecular sequencing efforts. 21 The results from a blood culture are
primarily used to discontinue or change the focus of antibiotic treatment, rather than
guide initial treatment decisions.5 This is of concern in a world of growing antibiotic
resistant organisms, as overuse of these drugs further contributes to the evolution of
resistance.22 After bacteria have been cultured, they can be identified using a wide variety
of clinical methods, which require further processing.
Bacterial cell culture requires laboratory facilities and highly trained personnel
who must follow a strict protocol in order to identify truly causative agents. Clinicians
must be aware of the potential for contamination and be able to discriminate between true
pathogens and contaminant species.16 The amount of time, training, and potential for
misleading results does not make cell culture a viable option for a point-of-care
diagnostic tool, especially for guiding treatment decisions in a timely manner.

1.2.2: The Gram Stain
The Gram stain, named after Christian Gram, is a staining protocol that can be
done quickly and easily. It has been in use since 1884. Gram-staining can be performed
to distinguish between the major groups of bacteria: Gram-negative, Gram-positive, or
Gram-indeterminate. Since the structure of each group of bacteria is different, they
respond to different types of antibiotics with varying degrees of success.23,24
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Understanding the major group of bacteria that is causing an infection can greatly help to
guide treatment decisions.
Gram-negative bacteria, with their LPS-rich outer membrane and thin
peptidoglycan layer, do not retain the primary Gram stain during the wash step. Gramnegative bacteria will appear red under a light microscope due to retention of the
secondary dye. Gram-positive bacteria, characterized by a thicker cell wall that is able to
retain the primary dye, will appear purple under the microscope.25 Gram-indeterminate
bacteria (also called Gram-variable bacteria), either do not respond to Gram staining or
appear both red and purple after Gram staining. Gram-indeterminate bacterial species
may have varying levels of peptidoglycan during growth, which would lead to
inconsistent Gram staining.26
While distinguishing between the major classes of bacteria is of the upmost
importance for selecting antibiotic treatment, the requirement of cell culture beforehand
makes Gram-staining an unlikely candidate for point-of-care diagnostics.

1.2.3: Enzyme-Linked Immunosorbent Assays
After amphiphilic biomarkers have been extracted from a host’s blood sample,
they can be detected via enzyme-linked immunosorbent assay (ELISA). ELISAs were
developed in the early 1970’s and are based on the immune response between antigens
and antibodies.27 There are many variations in ELISAs, but the overarching principle,
which remains consistent between these, is described here. A microwell plate is coated
with the antigen of interest, such as LPS. An epitope-specific primary antibody is then
added to detect the antigen. The primary antibody can be conjugated to an enzyme, such
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as horseradish peroxidase (HRP) for colorimetric or luminescent detection, or an enzymeconjugated secondary antibody may be used for colorimetric detection.28 Figure 3 shows
the detection of LPS via ELISA in a schematic. ELISAs are colorimetric and use the
color change upon the cleavage of the substrate by an enzyme conjugated to the targeting
antibody as a read-out. Modified immunoassays which use fluorescence labels attached to
recognition ligands and antibodies have also been developed, and sometimes can offer
greater sensitivity over colorimetric assays.
While useful for the detection of amphiphilic bacterial biomarkers, there are some
limitations associated with the use of ELISAs. Many amphiphilic biomarkers do not
adhere well to ELISA plates, which are designed for protein-based hydrophilic
interactions. This commands the need for sandwich assays: the requirement of two
recognition ligands per target antigen, making the approach complex and not adaptable to
small molecule detection. Low sensitivity and reproducibility are known to be issues
when detecting amphiphiles via ELISA.29 It is speculated that the amphiphilic
biochemistry of these biomarkers causes inconsistent binding to microwell plates.

Figure 3: Schematic of an indirect ELISA with LPS as the antigen of interest. A
microwell is coated with LPS, and a primary antibody is used to bind LPS. A
secondary antibody conjugated to the enzyme horseradish peroxidase (HRP) is used
for colorimetric detection when it reacts with the substrate.
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Additionally, amphiphiles form micelles in aqueous solutions, which could block
antibody binding via steric hinderance.30 In order to detect physiologically-relevant
concentrations of biomarkers, a more sensitive method should be used.

1.2.4: Polymerase Chain Reaction
Polymerase chain reaction (PCR) is another technique for the detection of
bacteria; however, this method detects nucleic acids instead of amphiphilic biomarkers.
PCR consists of three major steps: 1) denaturation of template DNA; 2) annealing of
primers for new DNA synthesis at a specific site; and 3) extension of new DNA strands
from the primers. Prior knowledge about pathogen-specific primers is necessary in order
to get a detectable signal. Multiple rounds of synthesis are performed in order to
maximize DNA yield. This process requires thermocycling to temperatures above which
DNA polymerase denatures; thus, the discovery of DNA polymerase from thermophilic
bacteria Thermus acquaticus (Taq) was key to the success of PCR.31,32
PCR can be performed on a variety of samples, including tissues, blood, and
microorganisms. Only trace amounts of DNA are required for PCR, making it an
extremely sensitive assay. It is also highly specific, as primers can be chosen to target a
gene known to be associated with the species of interest. Additionally, the materials
needed to perform PCR are inexpensive and fairly easy to use. 33
While PCR is valuable, it does have limitations. Primer design is dependent upon
prior sequencing data from the pathogenic species, and some primers can non-specifically
bind to sequences similar to the target DNA.33 For a point-of-care diagnostic tool, PCR
may be too specific. Primers would need to be available for a variety of pathogenic

10
bacteria. With the evolution of antimicrobial resistance and the adaption of bacterial
pathogens, the likelihood of PCR primers failing is a constant threat. Also, pathogenspecific nucleic acid sequences can sometimes be present in the absence of viable
organisms, causing a false positive result. PCR cannot be applied for the detection of
proteins. Detection of conserved amphiphilic biomarkers can allow for the fast detection
of major classes of bacterial infections, yielding enough information for accurate
treatment.

1.3: Waveguide-Based Biosensor as a Deployable Diagnostic Tool
1.3.1: Sensor Technology
A waveguide-based optical biosensor, developed by our team at the Los Alamos
National Laboratory, has the ability to quickly detect amphiphilic biomarkers extracted
from patient blood samples by using tailored and novel assay mechanisms. As an optical
biosensor, the technology measures changes in light due to the binding of an analyte with
a fluorescently-labeled reporter molecule.2,8 The sensor technology is based on the total
internal reflection of light when it passes through a boundary between materials with
different refractive indices at a critical angle of incidence. LANL’s biosensor utilizes a
planar optical waveguide, comprised of a guiding layer that has a higher refractive index
than the substrate layers.8 Under total internal reflection, light travels along the guiding
layer, and an electromagnetic field (the evanescent wave) is generated off the substrate
layers. The evanescent field decays exponentially as distance from the surface increases
to about 100nm.34 It is within this evanescent field that biomarkers captured by
fluorescently-labeled antibodies can be detected. The small area of detection minimizes
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background signals, ensuring a more accurate diagnosis. 11 Figure 4 shows a cross-section
of a planar optical waveguide with total internal reflection of light.
LANL’s waveguide platform has been used to detect not only PAMPs (including
LPS, LTA, and LAM), but other molecules of interest such as the carcinoembryonic
antigen (a breast cancer biomarker), toxins such as the cholera toxin, and the protective
antigen/lethal factor associated with Bacillus anthracis infection.7,8,10,35–38 Because of the
utility of this sensor, members of our team are developing a modular instrument for
deployable applications. This work includes scaling down and ruggedizing the benchtop
set up for field transport and use.

Figure 4: Cross-section of a planar optical waveguide. At a critical angle of
incidence, total internal reflection of light occurs in the waveguide layer, and an
evanescent field extends off the surface.

1.3.2: Waveguide-Based Assays
Two novel immunoassays have been developed at LANL for the detection of
bacterial infections: lipoprotein capture and membrane insertion. Both assays can be
performed on the waveguide-based optical biosensor, where biomarkers of interest are
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immobilized on the waveguide surface and detected by fluorescently-labeled antibodies
within the evanescent field. However, both assays can be adapted to other sensor
platforms that offer adequate sensitivity for the detection of low prevalence pathogen
biomarkers in complex samples.
Lipoprotein capture assays manipulate the natural affinity of amphiphilic
biomarkers with lipoprotein carriers in blood. A functionalized lipid bilayer is applied to
the flow cell of the waveguide, onto which an anti-lipoprotein antibody is conjugated.
The sample is added, and lipoprotein-biomarker complexes are captured by the antilipoprotein antibody. A fluorescent anti-biomarker antibody, excited by the light coupled
into the waveguide, serves as the reporter. 2 Since lipoprotein capture assays pull down
already existing lipoprotein-biomarker complexes, there is no need to perform
amphiphile extraction on the sample (our benchtop sample processing); however, prior
knowledge about which lipoprotein (HDL, LDL, etc.) associates with the biomarker of
interest is necessary. Additionally, biomarker epitopes could be embedded within the
lipoprotein carriers, causing them to evade detection.
Membrane insertion assays are based on the amphiphilic chemistry of bacterial
biomarkers. A lipid bilayer is applied to the flow cell of the waveguide to serve as a
capture surface. After the biomarkers are extracted from their lipoprotein complexes, they
are applied to the flow cell and naturally associate with the lipid bilayer. Only one
antibody is needed for membrane insertion assays: a fluorescent anti-biomarker
antibody.11,38 While membrane insertion assays do require sample preparation, they are
more sensitive and accurate at detecting bacterial infections. It is more likely that critical
epitopes will be exposed for detection, since the biomarkers are unbound from their
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lipoprotein carriers. Membrane insertion also requires less reagents, time, and lipid
bilayer surface preparation.11 Figure 5 compares the two assays as they would be
performed on LANL’s waveguide-based optical biosensor.

Figure 5: Two novel waveguide-based assays, membrane insertion (left) and
lipoprotein capture (right) can detect biomarkers of interest from bacteria.

Because it is not always known which lipoproteins the bacterial biomarkers
associate with in serum, membrane insertion assays are preferred for point-of-care use
over lipoprotein capture assays. By performing sample processing before the membrane
insertion assay, the amphiphilic biomarkers of interest can be directly detected. Figure 6
displays the overall processing and detection overview.
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Figure 6: Processing and detection overview. A) Within a patient’s blood sample,
lipoproteins sequester amphiphilic biomarkers of interest. B) Sample processing
liberates biomarkers from the lipoprotein complexes they form in serum. A mixture of
chloroform and methanol is used for the process. Lipoproteins tend to associate with
methanol, since it is the more hydrophilic solvent, while amphiphiles associate with
chloroform, which is more hydrophobic. C) Our novel membrane insertion assays
directly detect amphiphilic bacterial biomarkers. A lipid bilayer is used to capture the
biomarkers of interest before adding a fluorescently-labeled primary antibody.
Detection can be done via ELISA, LANL’s waveguide-based optical biosensor, or
otherwise.

1.3.3: Benchtop Sample Processing Methods
Before amphiphilic biomarkers can be detected from a host’s sample, they must
be extracted from the lipoprotein complexes they form in serum. 7 Our current sample
processing method is a modification of the Bligh-Dyer lipid extraction protocol, a
commonly used lipid extraction method from 1959. The Bligh-Dyer method relies on
solvents to separate lipids from other biological molecules. An aqueous sample is mixed
with chloroform and methanol in a volumetric ratio of .8:1:2, respectively. Bligh & Dyer
(1959) found this ratio to be ideal to form a biphasic solution, which can then be
manipulated to separate lipids from other biological molecules. 39 In comparison to
methanol, chloroform is hydrophobic, and lipids associate with the chloroform layer. 40
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By choosing which layers of the biphasic solution to work with, one can successfully
isolate molecules of interest.
As displayed in Figure 7, the modified Bligh-Dyer method for lipid extraction
involves multiple mixing, centrifugation, and pipetting steps, as well as chemicals
including chloroform and methanol. This protocol requires highly trained personnel to
ensure successful biomarker extraction. The manual steps also introduce an opportunity
for mistakes, which is of concern when handling potentially infectious blood. While
useful for benchtop assay development, an automated biomarker extraction would be
superior for deployable use.

Figure 7: A detailed schematic of benchtop sample processing. A) The first major
step of sample processing is to separate serum from blood. B) The second major step
of sample processing is serum treatment for biomarker extraction. 1) Serum is added
to a mixture of chloroform/methanol in a .8:1:2 ratio (by volume); 2) After mixing by
pipette, the tube is spun at 5500RPM for 1 minute and the supernatant is discarded. 3)
The lipid pellet is re-suspended in 1XPBS. 4) A short spin (5 sec) sends debris to the
bottom of the tube, and the supernatant is used in membrane insertion assays.
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1.4: Centrifugal Microfluidics
1.4.1: Centrifugal Microfluidics for Automation
Centrifugal microfluidics, also called “Lab-on-a-CD” or “Lab-on-a-Disc,” is a
promising field of research for the automation of a variety of biological processes,
including assays and sample preparation. Mixing, metering, and phase separations can be
automated by controlling the spin profiles of the device. 41 Other advantages include the
fact that minimal instrumentation is needed, the devices are efficient at removing trapped
air bubbles, and the centrifugal force is inherently effective at density-based
separations.42
Centrifugal microfluidic designs are especially appealing for point-of-care and
deployable diagnostics. Lack of clean water, dusty environments, unstable temperatures,
and fluctuating power supplies are all limitations of resource-poor areas. Centrifugal
microfluidic platforms can help overcome these limitations due to the low volume
requirements, ease of use, and fast processing time of the device. 43 Because of this,
centrifugal microfluidic platforms can expand the types of assays that can be performed
in isolated (and often disease-burdened) regions of the world.

1.4.2: Introduction to centrifugal microfluidic techniques
Forces: Centrifugal, Coriolis, Euler
Multiple forces act on the contents of centrifugal microfluidic devices. These
forces can be manipulated to control the flow of fluids within the device. The most
obvious force is the centrifugal force itself, which acts radially outward during rotation of
the disc.42 A second force, the Coriolis force, acts on fluids when the device is spun at
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relatively higher revolutions per minute (RPM).41 The Coriolis force acts perpendicularly
to the angular rotational frequency (ω) and the fluid velocity. The third major force is the
Euler force, which acts proportionally to the rotational acceleration.44 Figure 8 depicts a
fictitious Lab-on-a-Disc and the forces acting upon it.

Figure 8: Schematic of a Lab-on-a-Disc and the forces acting on a mass (m) when the
disc is spinning. Figure adapted from Strohmeier et al. (2015).

Unit Operations: Pumping, Valving, Mixing, Flow Switching
Unit operations refer to the basic functions that can be embedded within a Labon-a-Disc design to achieve the function of interest. The major forces (Centrifugal,
Coriolis, and Euler) can be manipulated to achieve unit operations at a specific time. 42
The centrifugal force can pump fluids from one location to another in a radial
direction towards the outer perimeter of the disc. The rate of flow depends on RPM,
location of the fluid reservoirs or channels, design geometry, and properties of the fluid
itself.41
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Valves can be used in order to further control the flow of fluid. Common valves
include capillary, hydrophobic, and siphon valves. Capillary valves function by balancing
capillary pressure and centrifugal pressure; if the centrifugal pressure is less than the
capillary pressure, fluid will not flow through and the valve is considered closed.
Conversely, when the centrifugal pressure exceeds the capillary pressure, fluid will flow
through and the valve is considered open. Hydrophobic valves consist of a narrow
hydrophobic channel, and also function based on the balance between capillary and
centrifugal pressure. Hydrophilic fluid will only flow past the hydrophobic region when
the RPM exceeds a critical value.41 Siphon valves move fluid from a reservoir further
from the center of rotation to a reservoir that is closer. These valves are based on
capillary action, and rely on a hydrophilic surface.45
Mixing is a common unit operation needed in biological processes. Diffusive
mixing alone is not usually sufficient for the small reagent volumes present in the
microfluidic disc.42 To adequately mix reagents, rapid oscillations of the disc, internal
paramagnetic particles, or external magnetic stirring can help to homogenize solutions.
Another common unit operation is flow switching, which is changing the
direction of specific fluids flowing into different chambers. This can be achieved by
manipulating the Coriolis force with a Y-shaped channel. Fluids will differentially flow
on either side of the Y-shape based on density.41

1.4.3: Challenges with Microfluidics at the Point-of-Care
While centrifugal microfluidic platforms offer a plethora of attractive solutions
for point-of-care diagnostics, they also come with a set of challenges. The environment
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inherent to resource-poor areas of the world imposes a set of limitations on the device.
Temperature fluctuations can affect biological reagents, which must be properly stored in
order to work effectively. Availability of a power supply cannot be relied upon; thus,
backup power or solar power must be considered in the device design. In extremely
remote areas, undertrained personnel are often responsible for sample procurement and
device operation; therefore, these processes must be as failsafe as possible. It is also
common to have low sample volumes available due to patient dehydration and
illnesses.43,45 Another consideration is the proper handling of waste: ideally, the waste
chamber on the disc could be pre-loaded with disinfectant to avoid worker exposure to
harmful chemicals or infectious patient samples.43
Beyond environmental challenges, design restrictions can limit the utility of
centrifugal platforms for point-of-care diagnostics. Adequately mixing multiple fluids is
difficult due to low fluid volume and viscosity. Diffusive mixing can be too slow for a
diagnostic tool that needs to process samples and give results quickly. Many valving
methods, such as siphoning, rely upon hydrophilic surfaces. This is often achieved by
treating a previously hydrophobic surface.45 Surface treatment can pose a problem for
deployable devices because it imposes a shelf life on the disc that may not be long
enough for a given application. Additionally, uneven surface treatment can affect the
performance of the device. Both environmental and design constraints must be overcome
in order to produce a fully functioning point-of-care diagnostic tool.
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Chapter 2: Motivation and Overview of Project
The motivation for this work is to provide a safe, rapid, and automated
microfluidic system for extraction of amphiphilic biomarkers from blood in order to
accurately detect bacterial infections at the point-of-care. In the developing world,
infectious diseases are one of the leading causes of death. 46 Many patients travel for
hours or days to reach a clinic to receive medical treatment. If the diagnostic tool used at
the clinic does not provide rapid results, and patients are asked to return later for outcome
management, many will be unable to do so.47,48 A timely diagnosis will therefore help
more patients receive suitable healthcare and will reduce the burden of infectious diseases
on resource-poor populations.
Antibiotic resistance is another issue that affects the developing world, perhaps
more so than in developed countries. The overuse of antimicrobials is considered a major
culprit in the evolution of antibiotic resistant organisms. 49,50 Broad spectrum antibiotics
are often prescribed as a comprehensive way of treating bacterial infections in rural
settings, where patients cannot wait for a definitive diagnosis.47 Other factors that may
contribute to antibiotic resistance is the ineffective regulation of pharmaceuticals, poor
drug quality, and environmental factors such as high temperatures. 49 Rapid and accurate
detection of bacterial infections may help to slow the spread of antimicrobial resistance.
Two specific aims will assist in the automation of blood sample processing, which
will contribute towards the overarching goal of preventing human illness from bacterial
infections: 1) automate and validate blood/serum separation on a centrifugal microfluidic
disc; and 2) automate and validate amphiphilic biomarker extraction from serum for use
with our membrane insertion assays. Figure 9 reviews the current sample processing

21
method. We identified multiple phase separations, waste and input steps, and a resuspension step. In this case, a phase separation is defined as a pellet separated from a
fluid phase. Table 1 displays the engineering considerations and challenges to take into
account when translating this process to an automated system.

Figure 9: Schematic of biomarker extraction process to be transferred to an automated
system. The process includes multiple phase separations, input, waste, and mixing
steps, and a re-suspension.

Table 1: Summary of the engineering challenges associated with automated
biomarker extraction and potential solutions to each
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Chapter 3: Materials and Methods

3.1: Device Designs for Phase Separations
3.1.1: Adaptations from Previously-Published Works
Initial designs to separate blood from serum were adapted from previous
studies.51,52 Hin et al.51 described a membrane-based device for the separation of serum
from blood and subsequent analysis of C-reactive protein (CRP). A commerciallyavailable Pall VividTM Plasma Separation Membrane was integrated into the inlet of a
microfluidic cartridge. This specific membrane was chosen since it is designed to
separate plasma from blood in a one-step process. Centrifugation was not required for
blood/serum separation; the blood cells get trapped in the membrane due to the force of
gravity.53 Low-speed centrifugation then whisks away purified serum for further
processing or analysis. This design may be suitable for point-of-care applications due to
the small blood sample needed (90µL), minimal electrical power needed, and simple use.
However, membrane integration was difficult to achieve consistently with this design,
and serum yield was extremely low for our application (<10µL).
Amasia and Madou52 developed a centrifugal microfluidic device for blood/serum
separation that relies on a siphon design to isolate the serum from the blood pellet. Two
milliliters of whole blood were added to the large sedimentation chamber. Blood/serum
separation was achieved via a specific RPM profile, reaching 3800RPM as a maximum
speed. Lower RPMs then prime and start the siphoning of serum into its own chamber.
The isolation of serum is ideal for further processing or on-chip analysis. Plasma purity,
measured by cell counting, was equal to or greater than plasma obtained from traditional
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separation in a tube. While promising, this design relies on a hydrophilic surface
achieved through oxygen plasma treatment in order for the siphon to function properly.
We found that the effect of plasma treatment had an inconsistent shelf-life, which is not
useful for a deployable device. Scalability was also an issue with this design, since it is
more useful to start with smaller volumes of blood from patients at the point-of-care.
When we scaled the design down, 350µL of blood was needed in order to yield 100µL of
serum. This amount of volume may be too much for some patients to give. Table 2
compares the two previously-published designs and summarizes their advantages and
disadvantages for our specific application of amphiphilic biomarker extraction.
Table 2: Designs adapted from previously-published works

3.1.2: Original Cross-Flow Filtration Design
A novel centrifugal microfluidic platform was developed based on the principals of
cross-flow filtration. During the process of cross-flow filtration, a fluid passes
tangentially across a filter. Tangential flow of blood is achieved via the centrifugal force
acting on the centrifugal microfluidic platform. Fluid components smaller than the
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membrane’s pores are driven through the filter as pressure builds due to the centrifugal
force, while larger components pass over the membrane without flowing through.54 In
contrast, dead-end filtration can result in clumping of particles that could clog the filter,
since the force of fluid flow is perpendicular to the membrane’s surface.55,56 Cross-flow
filtration decreases the chances of clogging, which in turn decreases the chances of red
blood cell lysis (an important consideration for our process). Cross-flow filtration allows
for decreased resistance across the filter, and therefore was chosen as a potential method
of phase separation.57 Figure 10 presents the concept of cross-flow filtrations as
compared to dead-end filtration.58

Figure 10: Cross-flow (left) vs. Dead-end (right) filtration for the separation of blood
from serum. Cross-flow filtration allows for less clogging. Figure adapted from ElSafty & Hoa (2012).

3.2: Fabrication Materials and Methods
After the adaptation of previous designs, an original centrifugal microfluidic platform
was developed for the separation of serum from blood and subsequent biomarker
extraction from serum. The cross-flow filtration platform consists of five structural layers
of plastic and one membrane layer held together by pressure-sensitive adhesive (3MTM).
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Layer schematics were drawn using SolidEdge 2D drafting software (Appendix 1).
Alignment holes were included on all layers for assembly on a jig. The layers were cut
using a CO2 laser cutter (M360, Universal Laser System) from previously laminated
stock acrylic (McMaster Carr), polycarbonate (McMaster Carr), and membrane sheets
(Sterlitech). After cutting, the plastic layers were cleaned by bath sonication for 15
minutes followed by a manual wipe down with isopropyl alcohol. Figure 11 displays a
schematic of the device layers and a photo of a fabricated device. Figure 12 presents a
unit of the multilayered cross-flow filtration device design, including a cross-section. Up
to six units can fit onto the 90mm diameter disc.

Figure 11: Original design for sample processing automation. A) Design layers
consisting of acrylic, Sterlitech membrane, and polycarbonate, cut for alignment; B) A
fully-fabricated device.
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Figure 12: One unit of the multilayered cross-flow filtration device design. A) Design
schematic drawn on SolidEdge 2D drafting software, where Wh is window height; B)
Cross-sectional schematic of one of the experimental chambers.

To achieve phase separation, the membrane integrated in the device acts as a
selective barrier to particles of certain sizes, while the supernatant can flow through to the
next chamber. Depending on the application, different membranes can be integrated, or
multiple filtration steps can be designed. Figure 13 uses the example of blood/serum
separation to display how the platform works for phase separations. Blood is added to the
inlet hole, which was cut to the diameter of a standard 1000µL pipette. When the disc is
rotated at a given RPM, the centrifugal force moves the blood across the integrated
membrane, which allows serum to flow through to the next chamber and prevents blood
cells from flowing through.
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Figure 13: A phase separation (blood/serum) on the centrifugal microfluidic disc via
cross-flow filtration. A) Blood is added to the inlet with a pipette; B) The disc spins at
4500RPM for 3 minutes, which provides the centrifugal force to cause tangential flow
of fluid; C) Blood cells are prevented from flowing through the membrane window,
while serum is able to, separating the two phases.

The membrane layers are made of Sterlitech hydrophilic polycarbonate and polyester
membranes with 5µm diameter pores. The polycarbonate membrane is coated with
polyvinylpyrrolidone to ensure hydrophilicity and sterilized with gamma irradiation,
ethanol, and autoclaved.59 The polyester membrane is sterilized in the same manner and
displays greater resistance to organic solvents, an important feature for biomarker
extraction, which utilizes chloroform. 60 The membrane sheets are reported by the
manufacturer to be between 3-24µm thick, making them delicate to work with.59,60 We
developed a novel method for membrane integration that consistently produces a surface
free from visible indentations or imperfections. The smoother membrane surface
increases phase separation reproducibility.
To incorporate the membrane layer, 4-5 drops of distilled water were pushed through
a syringe filter onto the base of the jig, which is made of acrylic. Using the jig holes for
alignment, the membrane with its protective top layer were placed gently down. Since the
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membrane is hydrophilic, it is pulled onto the base of the jig by the water through
adhesion. The protective layer was able to be removed without disturbing the membrane
underneath. The next acrylic layer of the device was then placed on top of the membrane,
glue-side down, bonding the two layers with a pressure-sensitive adhesive. The nowsealed layers were removed from the jig and allowed to dry membrane-side up for 20 to
30 minutes at room temperature. The rest of the acrylic and polycarbonate layers were
added in a similar fashion and fully sealed with a hand roller as necessary. Figure 14
displays the fabrication process for membrane integration.

Figure 14: Fabrication process for consistent membrane incorporation; A) The jig was
prepared with 5 drops of distilled water pushed through a syringe filter; B) The
hydrophilic nature of the membrane caused it to lie flat on the jig; C) The next acrylic
layer was bonded with a resulting smooth membrane surface; D) Using the jig for
alignment, additional layers were added in a similar fashion.
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3.3: Device Functionality Testing
Device functionality was verified in a series of experiments that determined ideal
RPM, time, membrane type, and geometric design parameters for phase separations, as
summarized in Table 3 and elaborated on in Appendix 2. The “window height” refers to
the size of the exposed membrane area (Figure 12A- Wh). In order to test different
conditions, the disc was placed on the jig, and 90 µL of whole sheep’s blood was pipetted
into each inlet hole. The inlets were designed to be the same diameter as the pipette tip in
order to create a seal and prevent leakage. A one-sided adhesive layer was aligned on the
top of the disc to seal all ports and prevent the escape of fluids during processing. A
microcentrifuge (Scilogex) was used to test different RPM and time profiles. A central
hole was cut into the microfluidic disc to fit over the rotor, and the cap from the
microcentrifuge was securely fastened over the disc.
Table 3: Experimental Parameters to Optimize Device Functionality
Membrane
Material
Polycarbonate
& Polyester

Membrane
Pore Size
2, 3, & 5
µm

Time
(min)
2–5

RPM
3500 – 5000

Window heightWh (mm)
3.5 – 5.5

Tested in 1 min
increments

Tested in 500
RPM increments

Tested in .5mm
increments

3.4: Blood/Serum Separation Efficiency
Serum purity, defined as the percentage of cells removed from whole blood, was
determined by using the TC20 Automated Cell Counter (BioRad). Cell counts from
whole sheep’s blood were compared to counts on serum from the microfluidic device,
and extraction efficiency was calculated using the following formula:
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Serum purity (%) =

(# of cells in whole blood - # of cells in serum)

x 100

(# of cells in whole blood)

Cell counts were also performed on commercially-available sheep serum (ThermoFisher)
and serum separated from blood by traditional benchtop methods, for comparison.
The automated cell counter has a maximum cell count of up to 1x10 7 cells/mL61,
so whole blood was diluted at 1:1000 in 1XPBS (ThermoFisher) in order to perform the
count (blood usually has 108 - 109 cells/mL).62 After dilution, 10μL of the blood in PBS
was pipetted onto slides compatible with BioRad’s TC20 Automated Cell Counter.
Whole blood cell counts were multiplied by 1000 to account for dilution. Serum was not
diluted in 1XPBS before pipetting 10μL onto compatible slides.

3.5: Biomarker Retention
3.5.1: Enzyme-Linked Immunosorbent Assays
Since the sample processing platform will eventually be integrated with our
amphiphile-detection assays, it was necessary to validate the detection of biomarkers
from samples processed on the microfluidic device as compared to those processed via
traditional benchtop methods. Because the bacterial biomarkers of interest are
amphiphilic in nature, this step also serves to validate device materials and surface
chemistry, by ensuring that the biomarkers were retained in the sample and not adsorbed
to the device.
Initial biomarker retention experiments were performed via enzyme-linked
immunosorbent assays (ELISAs) as a rapid way to confirm the microfluidic materials
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chosen were applicable for our sample processing. Lipopolysaccharide from Salmonella
typhimurium was purchased from List Biological Laboratories, Inc., spiked in 1XPBS
and horse serum at 50 µg/mL, and incubated at room temperature for one hour. After
incubation, the serum was mixed with chloroform and methanol as per the Bligh & Dyer
ratio. Half of the processed serum was used on the microfluidic device for lipid pellet
precipitation, while the other half was used to complete benchtop processing. In each
case, the serum/chloroform/methanol mixture was spun at 5500RPM for 1 minute (either
on the microfluidic device or in a microcentrifuge tube). The pellet was re-suspended in
100 µL 1XPBS (again, either on the microfluidic device or the microcentrifuge tube) and
50 µL of the resulting solutions were pipetted into the wells of a 96-well polystyrene
plate (ThermoFisher Scientific) and incubated overnight at 4 oC.
After overnight incubation, the plate was washed three times with wash buffer
(1XPBS + 0.5% Tween-20, Sigma-Aldrich), 200 µL of blocking buffer (1XPBS + 0.05%
Tween-20 + 0.5% BSA) was pipetted into each experimental well, and the plate was
incubated at room temperature for 1 hour. The blocking buffer was discarded and 100 µL
of anti-Salmonella monoclonal primary antibody (PAI-7244, ThermoFisher Scientific) at
a dilution of 1:1000 in 1XPBS was added to each well. After another 1 hour incubation,
the plate was washed three times using wash buffer. One-hundred µL of anti-rabbit
polyclonal secondary antibody (SouthernBiotech) conjugated to horseradish peroxidase
(HRP) was added to each well and incubated for 45 minutes. The plate again washed
three times, 100 µL of 1-step TMB ELISA substrate (ThermoFisher Scientific) was
added to each well, and the color developed within 20-30 minutes. Two molar sulfuric

32
acid was added to each well to stop the reaction, and absorbance was measured on the
Versa max plate reader (Molecular Devices, LLC) at 450nm.

3.5.2: Waveguide-Based Optical Biosensor Assays
Continued experiments were performed on Los Alamos National Laboratory’s
waveguide-based optical biosensor, which has been previously shown to detect
biomarkers from Gram-negative, -positive, and -indeterminate bacteria at low,
physiologically-relevant concentrations.7,10,11,38 Planar optical waveguides with a silicon
oxynitride (SiONx) film were prepared by nGimat (Atlanta, GA). Validation was
performed using a model biomarker, lipoarabinomannan (LAM), the virulence factor
associated with Mycobacterium tuberculosis. Stock LAM (19kDa) was procured through
BEI Resources. Two LAM primary antibodies (171 and 24) were purchased from FIND
and prepared in a 15nM cocktail in wash buffer (.5% BSA/1XPBS) for use on the
waveguide. Dioloeyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-Dioleoyl-sn-glycero3-phasphoethanolamine-N-(cap biotinyl) (cap-biotinyl-PE) were purchased from Avanti
Polar Lipids, Inc. Whole sheep’s blood in Alsever’s anti-coagulant solution (2.05%
dextrose, 0.8% sodium citrate, 0.0055% citric acid, 0.42% sodium chloride) was
purchased from ThermoFisher Scientific.
Waveguide surfaces were cleaned and functionalized with a lipid bilayer as
described in previously-published works.35,37,38 To do so, waveguides and coverslips were
cleaned by bath sonication for 5 minutes each in chloroform, ethanol, and distilled water.
They were then dried with argon gas and cleaned by UV-ozone (UVOCS Inc.) for 40
minutes. Flow cells were assembled by bonding a silicone gasket in between clean
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waveguides and coverslips. The lipid bilayer was prepared from 5mM stock DOPC and
cap biotinyl-PE (both in CHCl3). Sixty µL 5mM DOPC and 0.6 µL cap biotinyl-PE were
added to a glass test tube using a syringe needle (cleaned with chloroform/ethanol 3 times
each). Chloroform was evaporated under argon gas, and the lipids were rehydrated in 600
µL 1XPBS for 30 minutes on a shaker plate. Lipids were then exposed to ten freeze-thaw
cycles by freezing in liquid nitrogen and thawing in warm water. The fluid was then
sonicated with a probe tip sonicator (Branson, 50% duty cycle) for 6 minutes to ensure
vesicle uniformity. Seventy µL of prepared lipids were pipetted into the assembled flow
cell and incubated overnight at 4oC to encourage bilayer stabilization. Whole sheep’s
blood was spiked with LAM to a concentration of .05 µM and incubated overnight at
4oC.
Each assay began by clipping the flow cell onto a custom holder and aligning the
laser for coupling of light. Two-hundred µL wash buffer (.5% BSA/1XPBS) was injected
through the flow cell and the background signal was measured. Two-hundred µL of
15nM FIND antibody cocktail was injected and incubated at room temperature for 20
minutes. The flow cell was washed, and the non-specific signal was measured. Whole
sheep’s blood containing LAM was separated into serum/blood using the microfluidic
device or by traditional methods, depending on the assay. For the microfluidic device, 90
µL serum was pipetted into each inlet hole, and the disc was spun at 4500 RPM for 3
minutes. For traditional methods, 500 µL whole blood was pipetted into a
microcentrifuge tube and spun at 4500 RPM for 3 minutes. The serum from each method
of separation was used for cell counting, and sample processing was finished by benchtop
methods for the first round of experiments. One-hundred and twenty µL of serum was
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mixed by pipetting with 150 µL chloroform and 300 µL methanol in low-retention
microcentrifuge tubes. The mixture was spun at 5500 RPM for 1 minute, and the
supernatant was discarded. The pellet containing amphiphiles of interest was resuspended in 120 µL of 1XPBS, which was injected into the flow cell of the waveguide
and incubated for 45 minutes at room temperature. After incubation, the flow cell was
washed, and the specific signal was measured. Biomarker retention experiments were
performed in the same manner for each major step of the sample processing procedure
performed on the microfluidic chip and compared to the benchtop sample processing
method.
For the second round of experiments, the second major step of sample processing
(amphiphile extraction), was performed on the microfluidic device. Whole sheep’s blood
containing a concentration of .05 µM LAM was incubated overnight at 4oC to use on the
microfluidic chip and for traditional methods. Blood/serum separation was performed in
the same way for microfluidic and traditional methods (4500RPM for 3 minutes, as
above). Serum from the microfluidic chip was removed with a pipette and mixed with the
correct ratio of chloroform:methanol in a microcentrifuge tube. The mixture was then
pipetted onto a second chip designed for amphiphile extraction, which was spun at 5500
RPM for 1 minute to obtain the lipid pellet. The pellets were re-suspended in 100 µL of
1XPBS each and removed from the chip for analysis on the waveguide. Serum from
traditionally-separated blood was removed from the microcentrifuge tube with a pipette,
and sample processing was completed via the benchtop (modified Bligh & Dyer) method.
Amphiphiles were also re-suspended in 150 µL 1XPBS and used for comparative
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analysis on our waveguide-based optical biosensor. A schematic of the experimental
conditions is presented in Figure 15.
After each waveguide experiment, relative signal intensity was calculated by
factoring out the background and non-specific binding signals. The following formula
was used:

Signal intensity =

(specific signal – background signal)
non-specific signal – background signal

Figure 15: Experimental set up for two conditions of sample processing. In the first
round of experiments (left), serum was separated from blood via benchtop methods
and on a microfluidic chip. Serum was removed from the tube or dics and sample
processing was finished on the benchtop. In the second round of experiments, serum
was again separated from blood via benchtop methods and on a microfluidic chip.
Lipid pellet separation then occurred on a second microfluidic chip or by traditional
benchtop methods. All biomarker solutions were detected on LANL’s waveguidebased optical biosensor.
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Chapter 4: Results and Discussion

4.1: Device Functionality
Successful separation of serum from blood was achieved by spinning the disc at
4500 RPM for 3 minutes with a window height of 4.0mm. A two-step filtration design
was determined to be more effective at separating serum from blood when compared to a
one-step method (Figure 16). An amphiphilic pellet was successfully obtained by
spinning the disc at 5500 RPM for 1 minute, after the addition of
serum:chloroform:methanol in a 0.8:1:2 volumetric ratio. The pellet was re-suspended in
1XPBS on the chip, and then removed for analysis. A one-step separation method was
sufficient for amphiphile extraction.

Figure 16: Schematics of one-step (A) vs. two-step (B) cross-flow filtration, and
photos of phase separations; A) The one-step filtration method was suitable for
amphiphilic pellet separation from chloroform/methanol supernatant; B) The two-step
filtration method was successful at separating serum from blood.
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4.2: Serum Purity
The first step of our sample processing procedure calls for serum to be separated
from blood. When compared to traditional centrifugation and to commercially-available
serum, the serum processed on our microfluidic platform had a significantly lower cell
count (p < 0.0179 for microfluidics vs. benchtop; p < 0.0128 for microfluidics vs.
commercial serum, Figure 17). Serum purity was calculated for benchtop methods of
separation and for microfluidic separation. Both methods yielded a high percentage of
cells removed from whole blood, greater than 99.99%, as shown in Table 4.

Cells/mL

Cell Counts
1.0E+10
1.0E+09
1.0E+08
1.0E+07
1.0E+06
1.0E+05
1.0E+04
1.0E+03
1.0E+02
1.0E+01
1.0E+00
Whole Blood

Serum- Microfluidics

Serum- Benchtop

Commercial Serum

Solution

Figure 17: Cell count averages (n=3) on whole sheep’s blood (6.8x10 9 cells/mL),
serum processed on the microfluidic device (1.27x105 cells/mL), serum processed by
benchtop methods (4.45x105 cells/mL), and commercially-available serum (1.27x105
cells/mL). All solutions were sourced from ThermoFisher.
Table 4: Serum Purity
Sample

Serum Purity (%)

Serum- Microfluidics

99.99813

Serum- Benchtop

99.99611
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We determined that our device is suitable for blood/serum separation, a common
first step of many sample processing methods, including amphiphile extraction from
whole blood. The serum processed on the microfluidic device had a lower cell count than
serum processed on the benchtop and commercially-available serum, as well as higher
serum purity.

4.3: Biomarker Retention
4.3.1: Enzyme-Linked Immunosorbent Assays
The preliminary biomarker retention experiments, performed via ELISA,
indicated that the device materials and surface chemistry are suitable for our application.
When compared to benchtop methods of biomarker extraction, serum and 1XPBS
containing 50 μg/mL of Salmonella typhimurium LPS processed on the microfluidic
device had a similar or higher absorbance. This implies that the device materials
including acrylic, polycarbonate, and the Sterlitech membrane did not adsorb a biomarker
of interest, LPS. This information helped to guide future designs using the same
materials. This experiment was performed on two different days using two different
microfluidic chips. Interassay variability was low for both benchtop and microfluidic
methods, indicating that both methods produce consistent signals. Figure 18 shows the
compiled absorptions for the microfluidic device versus benchtop method performed on
two different days, as well as interassay variability. The higher the absorption, as read on
a plate reader at 450nm, the greater amount of analyte present in the sample.
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A

Sterlitech membrane device validationS. typhimurium LPS at 50μg/mL
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Microfluidics
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LPS in serum – 8.76%

LPS in serum – 6.42%

LPS in PBS – 3.94%

LPS in PBS – 5.16%

Figure 18: A) Absorbance at 450nm on LPS spiked in serum and 1XPBS on the
microfluidic device vs. benchtop methods. Higher absorbance indicates higher
concentration of biomarker retained in the serum sample; B) Interassay variability for
conditions tested.

4.3.2: Waveguide-Based Optical Biosensor Assays
Biomarker retention was further validated for each step of the sample processing
procedure performed on the microfluidic chip and compared to results from the benchtop
method as measured on LANL’s waveguide-based optical biosensor.
After serum from the microfluidic device was determined to be purer than serum
from the benchtop or commercially-available serum (Figure 17), and device materials
were considered suitable (Figure 18), we further validated the microfluidic chip by
testing for biomarker retention in the sample under different conditions.
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Lipoarabinomannan (LAM) was spiked in whole blood at .05μM before separating serum
from blood on the microfluidic device. The same blood was used for benchtop
blood/serum separation in microcentrifuge tubes. After separation, the serum was
processed by benchtop methods and analyzed on our waveguide-based optical biosensor,
as described in the Methods Section. There was no statistically significant difference
between LAM levels in serum processed on the microfluidic device vs. by benchtop
methods (p < .9392, Figure 19), indicating that the device’s materials and surface
chemistry are suitable for our application.

Figure 19: Signal intensity (n=3) on whole sheep’s blood separated on the
microfluidic device vs. benchtop methods. Higher intensity indicates higher
concentration of biomarker retained in the serum sample.

To validate the second step of sample processing, amphiphile extraction, LAM
was again spiked in whole sheep’s blood at a concentration of .05μM for use on the
microfluidic device and for benchtop extraction. Blood/serum separation was performed
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on both the chip and by traditional methods. Serum from the chip was removed and a
mixture of chloroform/methanol was added to the serum. The mixture was then pipetted
onto a second chip designed for amphiphile pellet precipitation, and the disc was spun at
5500RPM for 1 minute. While the microfluidic chip was able to successfully separate the
lipid pellet from the solvent mixture (Figure 16A), it was difficult to re-suspend the pellet
on-chip with 1XPBS. For this reason, waveguide-based biosensor assays that accurately
compare the benchtop methods to the microfluidic chip were not able to be performed.
The microfluidic chip was able to function as predicted, but a new design that
incorporates an easier way to re-suspend the pellet is needed.
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Chapter 5: Conclusions and Future Work
The goal of this research was to design and demonstrate proof of concept for the
automation of blood sample processing. In the benchtop method of sample processing,
amphiphilic biomarkers of interest are extracted from whole blood for detection of
bacterial infections via membrane insertion assays. For the automation of this process,
two specific goals were established: 1) automate and validate blood/serum separation on
a centrifugal microfluidic disc; and 2) automate and validate amphiphilic biomarker
extraction from serum for use with our membrane insertion assays.
In this work, a semi-automated sample processing platform was designed and
shown to extract amphiphilic biomarkers of interest from whole blood. The platform
requires only 90µL of whole blood to account for potentially dehydrated patients. It is
simple to manufacture, modular, disposable, pump-free, and does not require the dilution
of blood. The platform is a promising design for complete automation of sample
processing at the point-of-care. The microfluidic device also meets certain criteria for
deployable applications: it is disposable, inexpensive, user-friendly, compact, and
requires low amounts of power (and could potentially be solar-powered).46,47
The first aim of this work was to separate serum from blood on a microfluidic
system. An original design based on the principles of cross-flow filtration was developed
to achieve this goal. Experimental parameters including RPM, time, geometric designs,
and membrane materials were tested (Table 3). Successful blood/serum separation was
achieved by spinning the disc at 4500RPM for 3 minutes with a window height (Figure
12A) of 4mm using Sterlitech’s 5μm pore polycarbonate membrane. A two-step filtration
system was superior in performance when compared to a one-step filtration (Figure 16).
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In terms of serum purity, serum from the cross-flow filtration platform produced serum
with a lower cell count than serum separated traditionally and commercially-available
serum (Figure 17). Biomarker retention in the blood sample processed on the
microfluidic device was performed first by enzyme-linked immunoassays (ELISAs) and
showed a similar signal to serum processed via the benchtop method. This step served to
validate the materials and surface chemistry of the device. Secondary biomarker retention
experiments were performed on the waveguide instrument, and again the signal was
similar between serum samples processed on the microfluidic device versus benchtop
methods (Figure 19).
The second aim of this work was to extract amphiphilic biomarkers of interest
from serum on a microfluidic system. The same cross-flow filtration design that was
developed for blood/serum separation was used for biomarker extraction, since both steps
involve a phase separation. Successful amphiphilic pellet precipitation and separation
from supernatant was achieved by spinning the disc at 5500RPM for 1 minute with a
window height of 4mm using Sterlitech’s 5μm pore polyester membrane. A one-step
filtration process was sufficient for this step. Validation still needs to be performed on
LANL’s waveguide-based optical biosensor, which is more sensitive than ELISAs, since
the pellet was unable to be re-suspended and removed from the microfluidic chip.8
Future work must be done on this platform in order to move towards a fully
automated system. Having two chips to perform two steps increases the possibility of
mistakes being made, so we have been working on designs that will incorporate both
major steps of sample processing onto one microfluidic chip. On our current chip for
amphiphile extraction, the pellet was difficult to re-suspend and remove for analysis.
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Better mixing schemes and aspiration techniques will need to be incorporated and tested
in future designs. Another future direction of this work will be to investigate reagent
storage on-chip in order to decrease user interaction with chloroform and methanol. This
could possibly be achieved by embedding blister packs into specific areas of the
microfluidic chip. A long-term goal of this work is to develop a fully integrated
microfluidic sample processing platform with our deployable waveguide-based optical
biosensor. A fully integrated system would eliminate any need for user intervention at the
point-of-care.
Certain aspects of the cross-flow filtration microfluidic platform make it easily
adaptable for other phase separations or sample processing methods. Throughout the
design process, a straightforward fabrication method that results in consistent device
layers was developed. The design itself can be modified to include one, two, three, or
more filtration steps, depending on the needs of the user. Chambers and reservoirs can be
adjusted to hold different volumes of liquid. In this way, our system can be described as
modular.
The separation of serum from blood is a common laboratory procedure that needs
to be performed. Our platform offers users a safer way to separate serum from blood,
especially when compared to using micro-hematocrit tubes, which are typically made of
glass and have the potential to shatter. A standard pipette can be used to remove serum
from our chip, making it easier to remove than from a hematocrit tube. This is useful for
any protocol that requires further processing of serum, including standard laboratory
blood tests such as total serum cholesterol, HDL, LDL, and triglycerides.
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In summary, the microfluidic platform presented in this research is a promising
design for automated bacterial biomarker extraction from blood, and could be applied to
other sample processing procedures. The microfluidics-based cross-flow filtration
platform provides the framework for future studies that could achieve a fully automated
system of extraction. This would be a safe, user-friendly, and rapid approach for removal
of bacterial biomarkers from patient samples at the point-of-care, which in turn would
provide invaluable information to guide treatment decisions.
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Appendix
Appendix 1: Microfluidic Device Layers (SolidEdge 2D)
Layers were drawn on SolidEdge 2D drafting software. Materials and laser specifications
were included for each layer to ensure consistent device layers.
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Appendix 2: Experimental Parameters
We took a systematic approach for optimizing experimental parameters. For example,
when comparing window height and time, all experimental combinations were tested
three times and photographs were taken. Cell counts were performed on each design and
averaged in order to determine the best combination of parameters.

